This study investigated the association between multiple indices of adiposity (both novel and established indices) and the risk of incident HF in a community-based cohort.

A study shows that epicardial adipose tissue volume is significantly associated with all-cause mortality and HF hospitalization in patients with HFmrEF and HFpEF.

The DIAMOND trial meets its primary endpoint and suggests that treatment with patiromer is beneficial to control serum potassium levels in HF patients with active hyperkalemia or history of hyperkalemia while treated with RAASi therapy.

This patient-level pooled analysis used data from 30 827 participants at risk of HF and showed that aspirin use was associated with a higher risk of incident fatal and non-fatal HF.

An exploratory analysis of the PARADISE-MI trial suggested that treatment with sacubitril/valsartan after an acute MI may reduce recurrent HF events compared to ramipril.

The FDA has accepted a supplemental New Drug Application and granted Priority Review for empagliflozin for the treatment of adults with HF independent of LVEF.

AHA 2021 This analysis of the EMPEROR-Preserved trail showed that empagliflozin reduced the primary endpoint of time to first event of CV death or HF hospitalization by 17%, compared to placebo, in HF patients with LVEF ≥50%.

AHA 2021 The CHIEF-HF study showed that canagliflozin improved symptoms in HF as measured by KCCQ-TSS. The benefits with canagliflozin were observed as early as 2 weeks and sustained until the end of treatment at 3 months.

AHA 2021 This randomized, sham-controlled study showed that mesenchymal precursor cells did not reduce recurrent decompensated HF events. However, non-fatal MI or non-fatal stroke and decreased cardiac death were reduced in specific subgroups.

AHA 2021 The EMPULSE trial showed that initiation of empagliflozin in patients hospitalized for acute HF resulted in a clinical benefit within 90 days, compared to placebo.

This study investigated the effects of statin therapy on 5-year mortality in patients with acute HF and found that statin therapy was associated with reduced mortality in patients with HFpEF and in those with an ischemic etiology of HF.

This phase II randomized study showed that empagliflozin improved vascular function parameters in patients with HF under office conditions and in 24h ambulatory measurements compared to baseline as well as compared to placebo.